
LCTX Stock Forecast & Price Target
LCTX Analyst Ratings
Bulls say
Lineage Cell Therapeutics is a clinical-stage biotechnology company that utilizes a proprietary cell-based manufacturing platform, AlloSCOPE, to develop and commercialize novel therapies for degenerative diseases. The company's broad pipeline and partnerships with leading companies, such as Roche and Genentech, demonstrate strong potential for success in the treatments of diseases such as geographic atrophy in dry age-related macular degeneration and sensorineural hearing loss. Lineage's strong financial position, with $55.8 million in cash and additional potential funding through warrant exercises, provides a solid foundation for continued growth and development in 2026 and beyond.
Bears say
Lineage Cell Therapeutics is facing several fundamental risks, including potential delays in clinical trials and regulatory approvals, the need for partnerships and/or additional financing to fund its research and development efforts, potential challenges in commercializing its pipeline products due to competition and market dynamics, and potential legal and intellectual property risks. Additionally, the company's financials show significant losses over the past several years, with negative operating cash flow and a low cash position, indicating potential financial risk. These factors contribute to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LCTX Analyst Forecast & Price Prediction
Start investing in LCTX
Order type
Buy in
Order amount
Est. shares
0 shares